Agios Pharmaceuticals, Inc. (FRA:8AP)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.93B -2.1% |
| Revenue (ttm) | 57.28M +78.3% |
| Net Income | -366.52M |
| EPS | -6.29 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 32.00 |
| Previous Close | 32.00 |
| Day's Range | 32.00 - 32.00 |
| 52-Week Range | 19.70 - 38.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of a... [Read more]
News
Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $52 from $54 and keeps a Buy rating on the shares. The tebapivat Phase 2…
Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial
08:17 EDT Agios Pharmaceuticals (AGIO) down 13% at $34.75 on topline results from tebapivat trial
Agios Pharmaceuticals announces topline results from tebapivat trial
Agios Pharmaceuticals (AGIO) announced topline results from the Phase 2 trial of tebapivat, an oral pyruvate kinase activator, in patients aged 16 years or older with sickle cell disease. The…
Agios Pharma to discontinue sickle cell disease treatment development
Agios Pharmaceuticals said on Tuesday it will stop development of its sickle cell disease treatment, sending its shares down 14% in premarket trading.
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in ...
Agios Pharmaceuticals rises 13.5%
Agios Pharmaceuticals (AGIO) is up 13.5%, or $5.04 to $42.43.
Leerink sees Priority Review designation as positive sign for Agios’ mitapivat
Leerink notes that Agios Pharmaceuticals (AGIO) announced the FDA granted Priority Review for the sNDA for mitapivat in sickle cell disease with a PDUFA date of 11/1/26 suggesting imminent approval.
H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat
H.C. Wainwright analyst Emily Bodnar notes that Agios Pharmaceuticals (AGIO) announced that the FDA accepted its sNDA for mitapivat, in sickle cell disease under the accelerated approval pathway with ...
Agios Pharmaceuticals rises 12.9%
Agios Pharmaceuticals (AGIO) is up 12.9%, or $4.81 to $42.20.
Agios Pharmaceuticals price target raised to $46 from $40 at BofA
BofA raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $46 from $40 and keeps a Buy rating on the shares. Company-compiled consensus of $26.9M appears achievable based on…
Agios Pharmaceuticals price target raised to $41 from $36 at Truist
Truist raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $41 from $36 and keeps a Buy rating on the shares as part of a broader research note updating…
Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
RBC Capital raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $32 from $28 and keeps a Sector Perform rating on the shares as part of a broader research…
Agios Pharmaceuticals granted priority review for mitapivat sNDA
Agios Pharmaceuticals (AGIO) announced that the FDA has accepted its supplemental new drug application for mitapivat, an oral pyruvate kinase activator, in sickle cell disease with a priority review. ...
U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease
FDA's PDUFA goal date is November 1, 2026 If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWI...
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit...
Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $54 from $50 and keeps a Buy rating on the shares. The company over the weekend presented numerous…
Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat
Agios Pharmaceuticals (AGIO) presented detailed results from the 52-week double-blind period of the global RISE UP Phase 3 trial of mitapivat. These efficacy and safety results, which include new tran...
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses showed patients in mitapivat arm had clinic...
Agios Pharmaceuticals Transcript: EHA 2026
The conference highlighted robust clinical data for mitapivat in thalassemia and sickle cell disease, including durable hemoglobin improvements, reduced transfusion needs, and a favorable safety profile. Strategic expansion into new indications and strong commercial execution position the company for growth in rare hematology.
Agios Pharmaceuticals Slides: FY 2026
Agios Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 13, 2026.
Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan
JPMorgan lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $31 from $36 and keeps a Neutral rating on the shares. The past few months have been active for…
Agios Pharmaceuticals Transcript: Status update
Announced a global license for cevidoplenib, a next-gen SYK inhibitor for ITP, with a capital-efficient deal structure and strong commercial synergies. Phase II data show durable efficacy and favorable safety, supporting phase III initiation in 2028.
Agios Pharmaceuticals Slides: Status update
Agios Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Agios Pharmaceuticals Press release: Status update
Agios Pharmaceuticals issued a press release on June 1, 2026, disclosing material business information to investors.
Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib
Agios Pharmaceuticals (AGIO) announced an agreement with Oscotec, headquartered in South Korea, to license the exclusive global rights to cevidoplenib, an oral spleen tyrosine kinase inhibitor. Agios ...